IP Library › Granted Patent US 6,939,670
Granted Patent B2
US 6,939,670 · App. 10/095,297 · Granted Sep 6, 2005

Cell-based detection and differentiation of lung cancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,939,670
App. No.
10/095,297
Granted
Sep 6, 2005
Kind
B2
Abstract

The present invention provides a method for detecting and differentiating disease states with high sensitivity and specificity. The method allows for a determination of whether a cell-based sample contains abnormal cells and, for certain diseases, is capable of determining the histologic type of disease present. The method detects changes in the level and pattern of expression of the molecular markers in the cell-based sample. Panel selection and validation procedures are also provided.

Claims (11)

1. A panel for detecting lung cancer, wherein:

(a) said panel comprises a plurality of probes each of which specifically binds to a marker associated with lung cancer,

(b) the pattern of binding of the component probes of the panel to cells in a cytology sample is diagnostic for the presence of lung cancer, and

(c) said plurality of probes comprises a probe that binds to cyclin A or a correlate marker thereof and at least two probes, each of which binds to a marker selected from the group consisting of SP-B, HERA, ER-related(p29) and correlate markers thereof as depicted in the correlation matrix shown in FIG. 4 .

2. A cell-based method for detecting lung cancer, comprising contacting cells from a cytology sample on one or more microscope slides with a panel comprising a plurality of probes and analyzing the pattern of binding of the component probes of the panel to cells in said cytology sample to detect lung cancer,

wherein said plurality of probes comprises a probe that binds to cyclin A or a correlate marker thereof and at least two probes, each of which binds to a marker selected from the group consisting of SP-B, HERA, ER-related(p29), and correlate markers thereof as depicted in the correlation matrix shown in FIG. 4 .

3. A panel for detecting lung cancer, wherein said panel comprises a plurality of probes each of which specifically binds to a marker associated with lung cancer, wherein:

(a) the pattern of binding of the component probes of the panel to cells in a cytology sample is diagnostic for the presence of lung cancer, and

(b) said plurality of probes comprises probes that bind to cyclin A, SP-B, HERA, and ER-related(p29).

4. A cell-based method for detecting lung cancer, comprising contacting cells from a cytology sample on one or more microscope slides with a panel comprising a plurality of probes and analyzing the pattern of binding of the component probes of the panel to cells in said cytology sample to detect lung cancer,

wherein said plurality of probes comprises a probe that binds to cyclin A and at least one probe that binds to a marker selected from the group consisting of SP-B, HERA, ER-related(p29).

Assignments (8)
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS Recorded Aug 25, 2010
From: GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT
To: HOLOGIC, INC.; R2 TECHNOLOGY, INC.; SUROS SURGICAL SYSTEMS, INC.; BIOLUCENT, LLC; DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS LIMITED PARTNERSHIP; CYTYC SURGICAL PRODUCTS II LIMITED PARTNERSHIP; CYTYC SURGICAL PRODUCTS III, INC.; CYTYC PRENATAL PRODUCTS CORP.; THIRD WAVE TECHNOLOGIES, INC.
Reel/Frame 024944/0315 →
11TH SUPPLEMENT TO PATENT SECURITY AGREEMENT Recorded Jul 1, 2009
From: HOLOGIC, INC.
To: GOLDMAN SACHS CREDIT PARTNERS L.P., AS COLLATERAL AGENT
Reel/Frame 022892/0922 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2009
From: MONOGEN INC.
To: HOLOGIC INC.
Reel/Frame 022742/0960 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2002
From: PRESSMAN, NORMAN J.; HIRSCH, KENNETH S.
To: MONOGEN, INC.
Reel/Frame 013139/0119 →